Anti-TNFα therapy of rheumatoid arthritis: What have we learned?

Annual Review of Immunology

Volumn 19, Issue , 2001, Pages 163-196

  Feldmann, M ^a   Maini, R N ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Anti TNF antibodies and inhibitors; Cytokines; Immunotherapy; Rheumatoid arthritis; TNF

Indexed keywords

CYTOKINE; ETANERCEPT; HYBRID PROTEIN; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LENERCEPT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARTILAGE DEGENERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG APPROVAL; ENZYME BLOOD LEVEL; IMMUNOTHERAPY; IN VITRO STUDY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CHEMOTAXIS, LEUKOCYTE; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GAMMA-CHAINS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOSUPPRESSIVE AGENTS; MICE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SAFETY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035056003     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.19.1.163     Document Type: Review

References (160)

1. Association of the B cell alloantigen DRW4 with rheumatoid arthritis
2. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
3. A molecular basis for MHC class II-associated autoimmunity
4. Rheumatoid arthritis: Nature or nurture?
5. Twin concordance rates for rheumatoid arthritis: Results from a nationwide study
6. Factors predicting a poor life prognosis in rheumatoid arthritis: An eight year prospective study
7. What is the natural history of rheumatoid arthritis?
8. Rheumatoid arthritis
9. An endotoxin-induced serum factor that causes necrosis of tumors
10. Tumor necrosis factor (TNF)
11. Human tumor necrosis factor: Precursor structure expression and homology to lymphotoxin
12. Tumor necrosis, cachexia, shock, and inflammation: A common mediator
13. The pathophysiology of tumor necrosis factors
14. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon
15. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis factor activity
16. The cytokines: An overview
17. The role of cytokines in normal and pathological situations
18. TNFα
19. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
20. A metalloproteinase disintegrin that releases tumour necrosis factor-alpha from cells
21. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia
22. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
23. IFN-γ enhances endothelial activation induced by tumor necrosis factor but not IL-1
24. IL-1α or tumor necrosis factor-α stimulate release of three NAP-1/IL-8-related neutrophil chemotactic proteins in human dermal fibroblasts
25. Enhancement of antigen- and mitogen-induced human T lymphocyte proliferation by tumor necrosis factor-α
26. Effects of recombinant murine tumor necrosis factor-α on immune function
27. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis
28. The interleukin-1 family: 10 Years of discovery
29. Rheumatoid arthritis
30. Role of cytokines in rheumatoid arthritis
31. Anti TNFα therapy of rheumatoid arthritis
32. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis
33. Tumor necrosis factor blockers in rheumatoid arthritis
34. Cytokines in rheumatoid arthritis
35. The synthetic metalloproteinase inhibitor BB-2275 blocks both p55 and p75 TNF receptor shedding, independent of its inhibitory effect on TNF processing
36. A human inhibitor of tumor necrosis factor α
37. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
38. Isolation and characterization of a tumor necrosis factor binding protein from urine
39. Interleukin-10
40. The transforming growth factors-beta
41. Recombinant human interleukin-11 attenuates the inflammatory response through down-regulation of pro-inflammatory cytokine release and nitric oxide production
42. IL-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology
43. Interleukin-1, tumor necrosis factor and their specific inhibitors
44. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
45. In sim hybridization of IL-6 in rheumatoid arthritis
46. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
47. Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis
48. Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and TNFα
49. Cytokines in synovial fluid. I. The presence of biologically active and immunoreactive IL-1
50. Tumour necrosis factor in synovial exudates
51. Cytokines in chronic inflammatory arthritis. IV. GM-CSF mediated induction of class II MHC antigen on human monocytes: A possible role in RA
52. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies
53. Low levels of interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis
54. Macrophage migration inhibitory factor in rheumatoid arthritis: Evidence of proinflammatory function and regulation by glucocorticoids
55. Immunoregulatory role of interleukin 10 in rheumatoid arthritis
56. Important immunoregulatory role of intedeukin-11 in the inflammatory process in rheumatoid arthritis
57. Correlation of histopathological features of pannus with patterns of damage in different joints in rheumatoid arthritis
58. Current comment: Pannus and pannocytes: Alternative models of joint destruction in rheumatoid arthritis
59. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-alpha
60. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha
61. Collagen-induced arthritis - What can it teach us?
62. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins
63. Involvement of endogenous tumour necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice
64. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
65. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
66. Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice
67. Therapeutic monoclonal antibodies
68. Pharmacoeconomics of drug therapy for rheumatoid arthritis
69. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
70. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha
71. An engineered human antibody for chronic therapy: CDP571
72. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen
73. Efficacy of a novel pegylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis
74. Soluble tumour necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
75. Recombinant soluble TNF receptor proteins protect mice from LPS-induced lethality
76. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-8TNF-RI): Novel high affinity TNF receptor designed for chronic inflammatory diseases
77. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis
78. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
79. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
80. Synergy between anti-CD4 and anti-TNF in the amelioration of established collagen-induced arthritis
81. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
82. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability
83. 54 Week clinical and radiographic results from the attract trial: A phase III study of infliximab (RemicadeTM) in patient with active RA despite methrotrexate
84. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CD571) in rheumatoid arthritis
85. Preliminary results of early clinical trials with the fully human anti-TNF monoclonal antibody D2E7
86. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis
87. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis - Results of a phase I study
88. Long-term efficacy and tolerability of multiple i.v. doses of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis
89. Long term treatment with the fully human anti TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis
90. Effect of a fully human anti TNFα monoclonal antibody on the local and systemic expression of TNFα and IL-1β
91. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
92. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
93. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
94. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial)
95. Etanercept in children with polyarticular juvenile rheumatoid arthritis
96. Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of a European phase II trial
97. Chronic TNF neutralization (up to 1 year) by lenercept (TNFR 55 IgG1, Ro 45-2081) in patients with rheumatoid arthitis: Results from open label extension of a double blind single-dose phase I study
98. Neutralization of TNF by lenercept (TNFR 55 TgGt, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: Results of a phase II trial
99. Loading/maintenance doses approach to neutralization of TNF by Lenercept (TNFR55-IgG1, Ro45-2081) inpatients with rheumatoid arthritis treated for 3 months: Results of a double-blind placebo controlled phase II trial
100. Immunogenicity of a human TNFR55-IgG1 fusion protein (Lenercept) in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients
101. Recombinant methionyl human tumor necrosis factor binding protein PE-Gylated dimer (TNFbp Dimer) in patients with active refractory rheumatoid arthritis
102. Biologic agents for treating rheumatoid arthritis. Concepts and progress
103. Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis
104. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice
105. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis
106. TNF-deficient mice develop anti-nuclear autoantibodies
107. Immunological intervention reveals reciprocal roles for TNFα and IL-10 in rheumatoid arthritis and SLE
108. Assessment of antibodies to dsDNA induced in rheumatoid arthritis (RA) patients following treatment with infliximab, a monoclonal antibody to TNF alpha
109. Regulation of cytokines, cytokine inhibitors, and acutephase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
110. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis
111. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
112. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis - Short term cellular and molecular effects
113. Brain-derived TNF alpha mediates nueropathic pain
114. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
115. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor a antibody in rheumatoid arthritis
116. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis
117. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
118. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis
119. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis
120. Anaemia of chronic disease in rheumatoid arthritis: In vivo effects of tumour necrosis factor a blockade
121. Interleukin 6 antibodies in rheumatoid arthritis
122. Complementarily-determining region (CDR) implantation: A theme of recombination
123. Making antibodies by phage display technology
124. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice
125. Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs
126. A new form of allotype of rabbit gamma-globulins apparently correlated with antibody function and specificity C
127. The mechanism of immunological paralysis
128. Cell-to-cell interaction in the immune response, X. T-cell-dependent suppression in tolerant mice
129. Cellular sites of immunologic unresponsiveness
130. Anti-TNFα monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): Results of a double-blind, placebo controlled multicenter trial
131. Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells
132. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor
133. Adenovirus mediated gene transfer of CTLA-4Ig fusion protein suppresses experimental autoimmune arthritis
134. Etanercept: Theapeutic use in patients with rheumatoid arthritis
135. Preliminary criteria for clinical remission in rheumatoid arthritis
136. Possible mechanism for the long-term efficacy of anti-TNF alpha antibody (cA2) therapy in RA
137. Interleukin-10 inhibition of the progression of established collagen-induced arthritis
138. Combining anti IL-1 and anti-TNF treatments provides better efficacy in rat adjuvant arthritis than does either agent alone
139. Angiogenesis: A critical process in the pathogenesis of RA - A role for VEGF?
140. Rheumatoid arthritis synovial stromal cells inhibit apoptosis and upregulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism
141. Inhibition of T cell apoptosis in the rheumatoid synovium
142. Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene
143. Molecular biology of cartilage and bone destruction
144. Pig interleukin-1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation and fever
145. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage
146. Actions of recombinant interleukin 1, intefieukin 2, and interferon gamma on bone resorption in vitro
147. Joint inflammation and cartilage destruction may occur uncoupled
148. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor α in the rabbit: Evidence for synergistic interactions between cytokines in vivo
149. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation
150. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
151. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
152. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
153. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
154. Infliximab for the treatment of fistulas in patients with Crohn's disease
155. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)